

## PULMONARY VEINS ISOLATION ALONE CONTINUES THE BEST APPROACH?



Pedro Silvério António<sup>1</sup>; Mafalda Carrington<sup>2</sup>; Tiago Rodrigues<sup>1</sup>; Joana Brito<sup>1</sup>; Gustavo Lima da Silva<sup>1</sup>; Luis Carpinteiro<sup>1</sup>; Nuno Cortez-Dias<sup>1</sup>; Ana Bernardes<sup>1</sup>; Fausto J Pinto<sup>1</sup>; João de Sousa<sup>1</sup> 1. Serviço de Cardiologia, Departamento de Coração e Vasos, Centro Hospitalar Universitário Lisboa Norte, Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa 2. Hospital do Espírito Santo, EPE, Évora

### Introduction

- The cornerstone of atrial fibrillation (AF) catheter ablation (CA) is the <u>complete pulmonary</u> <u>veins isolation (PVI)</u>, applying circular lesions around their antrum.
- In **persistent and long-standing persistent AF**, more extensive ablation has been advocated, that may include <u>empirical additional linear lesions in the left atrium (LAL)</u>.
- Moreover, <u>cavo-tricuspid isthmus ablation (CTA</u>) may be performed even in the absence of previous atrial flutter (AFL).
- However, the benefit versus PVI alone, during the first procedure, is not demonstrated.

#### Purpose

To compare arrhythmia-free survival between PVI alone versus PVI complemented with LAL and/or CTA.

### Methods

• Prospective single-center study


# 2004 to 2018

**Population**: pts with AF submitted to a first point-by-point CA, with or without LAL or CTA. **Exclusion**: pts with <u>atypical</u> flutter.

**Follow-up**: Holter/event monitors periodically at <u>6 and 12 months</u> and then annually until 5 years of follow-up.


**Primary endpoint:** arrythmia-free survival (<u>absence of documentation of more than 30</u> <u>seconds of AF, flutter or atrial tachycardia</u>).

**Statistical analysis:** <u>Cox regression</u> and <u>Kaplan-Meier survival</u> were used to compare the success of ablation as a function of the clinical type of AF.



Procedures	N (8%)
PVI	293 (100%)
LAL	47 (16%)
СТА	83 (28.3%)

The **12 and 36-months** CA success rate were **70.8% and 52.9%**, and there were significant differences depending on the ablation strategy.



#### The risk of AF recurrence:

- <u>2 times superior</u> in pts submitted to PVI and LAL strategy (HR: 2.27; IC95% 1.38-3.75; P=0.001).
- ▶ 4 times superior in those with a strategy with PVI+CTA+LAL (HR: 4.17; IC95% 1.79-9.72; P=0.001).

## Conclusion

Treating AF with CA therapy using PVI alone was superior to a strategy with combined LAL and to CTA and LAL.

LAL strategy seemed to adversely affect the long-term success rate.